Literature DB >> 25160793

Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia.

Fiorina Giona1, Giuseppe Saglio, Maria Luisa Moleti, Alfonso Piciocchi, Massimiliano Rea, Mauro Nanni, Deborah Marzella, Anna Maria Testi, Sabrina Mariani, Marica Laurino, Daniela Diverio, Enrico Gottardi, Robin Foà.   

Abstract

Entities:  

Keywords:  BCR-ABL1; childhood; chronic myeloid leukaemia; imatinib; treatment-free remission

Mesh：

Substances：

Year:  2014        PMID： 25160793     DOI： 10.1111/bjh.13103

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

Review 1.  Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children.

Authors:  Lia N Phillips; Nobuko Hijiya
Journal:  Paediatr Drugs       Date:  2021-04-26       Impact factor: 3.022

2.  Outcome prediction of chronic myeloid leukemia (CML) in children.

Authors:  Wing-Yan Leung; Daniel Ka-Leung Cheuk; Frankie Wai-Tsoi Cheng; Alex Wing-Kwan Leung; Ka-Ho Chiu; Karin Kar-Huen Ho; Chak-Ho Li; Godfrey Chi-Fung Chan
Journal:  Ann Hematol       Date:  2022-06-01       Impact factor: 4.030

3.  New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia.

Authors:  Cristina Panuzzo; Gisella Volpe; Elisa Cibrario Rocchietti; Claudia Casnici; Katia Crotta; Sabrina Crivellaro; Giovanna Carrà; Roberta Lorenzatti; Barbara Peracino; Davide Torti; Alessandro Morotti; Maria Pilar Camacho-Leal; Paola Defilippi; Ornella Marelli; Giuseppe Saglio
Journal:  Oncoscience       Date:  2015-11-11

Review 4.  Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.

Authors:  Francesca Carofiglio; Antonio Lopalco; Angela Lopedota; Annalisa Cutrignelli; Orazio Nicolotti; Nunzio Denora; Angela Stefanachi; Francesco Leonetti
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 5.  Paediatric chronic myeloid leukaemia: Is it really a different disease?

Authors:  Deepam Pushpam; Sameer Bakhshi
Journal:  Indian J Med Res       Date:  2019-05       Impact factor: 2.375

6.  Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia.

Authors:  Yeojae Kim; Seongkoo Kim; Jong Mi Lee; Ari Ahn; Jae Won Yoo; Jae Wook Lee; Bin Cho; Nack-Gyun Chung; Yonggoo Kim; Myungshin Kim
Journal:  Front Pediatr       Date:  2022-07-27       Impact factor: 3.569

7.  Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection.

Authors:  Susanna Vuorenoja; Kim Vettenranta; Olli Lohi
Journal:  Cancer Rep (Hoboken)       Date:  2022-07-07

Review 8.  Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.

Authors:  Elena Inzoli; Andrea Aroldi; Rocco Piazza; Carlo Gambacorti-Passerini
Journal:  Am J Hematol       Date:  2022-04-12       Impact factor: 13.265

Review 9.  Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.

Authors:  Jorge Cortes; Delphine Rea; Jeffrey H Lipton
Journal:  Am J Hematol       Date:  2018-11-25       Impact factor: 10.047
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.